Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some identity/mechanistic timing descriptors for NOVOLOG (insulin aspart) are supported, but multiple claims comparing NOVOLOG to “Novolin” and non-interchangeability are not verifiable against the provided NOVOLOG label text, and the claim set omits/does not evaluate major labeled safety elements.
Category Scores
Accurate Statements
Novolog is insulin aspart.
11 DESCRIPTION ("NOVOLOG (insulin aspart)")
Novolog is a fast-acting insulin.
11 DESCRIPTION ("insulin aspart is a rapid-acting")
Novolog is used around meals.
12.3 Pharmacokinetics (Figure description: "pre-meal dose of NOVOLOG ... injected immediately before a meal")
Because Novolog is fast-acting, it is designed to start working relatively quickly after injection.
12.3 Pharmacokinetics (median time to maximum concentration 40 to 50 minutes) and 11 DESCRIPTION (rapid-acting)
Unsupported Statements
Novolog and Novolin are different insulin products.
Not supported by the provided NOVOLOG label sections; no NOVOLIN product labeling provided for comparison.
Novolog and Novolin use different active ingredients.
Not supported by the provided NOVOLOG label sections; no NOVOLIN active ingredient details provided.
Novolin is a brand name used for older-generation insulins.
Not supported by the provided NOVOLOG label sections.
Novolin products come in different types, including regular and NPH.
Not supported by the provided NOVOLOG label sections.
The Novolin types regular and NPH are not the same as insulin aspart.
Not supported by the provided NOVOLOG label sections; no NOVOLIN product ingredient/identity information provided.
Novolin products vary by type, including regular insulin (shorter-acting).
Not supported by the provided NOVOLOG label sections.
Novolin products vary by type, including NPH (intermediate-acting).
Not supported by the provided NOVOLOG label sections.
Regular insulin and NPH follow different timing patterns.
Not supported by the provided NOVOLOG label sections.
Novolog and Novolin are not interchangeable without a prescriber’s direction.
Not supported by the provided NOVOLOG label sections; no interchangeability wording or NOVOLIN-specific labeling provided.
Contradictions
Important Omissions
Evaluation of NOVOLOG FDA-labeled contraindications (Section 4), including hypoglycemia episodes and hypersensitivity.
Importance:
High
Evaluation of boxed warnings and warnings/precautions (Section 5) and other key safety labeling elements.
Importance:
High
Evaluation of NOVOLOG dosage and administration labeling (Section 2) beyond meal-timing/PK descriptions.
Importance:
Moderate
Evaluation of use in specific populations (e.g., pregnancy/lactation, pediatric, geriatric) and adverse reactions/monitoring, which are major labeling components.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Non-verifiable claims about NOVOLIN identity/interchangeability could lead to misinterpretation, and the audit does not cover major NOVOLOG safety labeling elements (contraindications/warnings/dosing/administration).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims about “Novolin” and interchangeability are not supported/assessable against the provided NOVOLOG label text.
Suggested Improvement
Restrict assertions to NOVOLOG-only statements supported by the provided label sections, or provide the exact FDA-approved label(s) for the specific NOVOLIN product(s) referenced (e.g., Novolin R/N/NPH) and relevant sections for interchangeability and active ingredient/timing.